You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 2, 2024

CLINICAL TRIALS PROFILE FOR LOPURIN

✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for LOPURIN

Subscribe to access the full database, or Sign Up
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00899431 ↗	Nonmyeloablative Stem Cell Transplantation for Chronic Lymphocytic Leukemia (CLL)	Terminated	Celgene Corporation	Phase 2	2009-05-06	The goal of this clinical research study is to learn if lenalidomide, when given with a stem cell transplant and chemotherapy (bendamustine, fludarabine, and rituximab), can help to control CLL. The safety of this treatment combination will also be studied.
NCT00899431 ↗	Nonmyeloablative Stem Cell Transplantation for Chronic Lymphocytic Leukemia (CLL)	Terminated	M.D. Anderson Cancer Center	Phase 2	2009-05-06	The goal of this clinical research study is to learn if lenalidomide, when given with a stem cell transplant and chemotherapy (bendamustine, fludarabine, and rituximab), can help to control CLL. The safety of this treatment combination will also be studied.
NCT01685411 ↗	Busulfan and Cyclophosphamide Followed By ALLO BMT	Terminated	Masonic Cancer Center, University of Minnesota	N/A	2013-01-01	This is a treatment guideline to allow routine clinical data to be collected and maintained in Oncore (clinical database) and the University of Minnesota Blood and Marrow Database as part of the historical database maintained by the department.
NCT03128879 ↗	Venetoclax and Ibrutinib in Treating Participants With High-Risk Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	Recruiting	AbbVie	Phase 2	2017-06-16	This phase II trial studies how well venetoclax and ibrutinib work in treating participants with high-risk chronic lymphocytic leukemia/small lymphocytic lymphoma. Drugs used in chemotherapy, such as venetoclax, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving venetoclax and ibrutinib may work better in treating participants with chronic lymphocytic leukemia/small lymphocytic lymphoma.
NCT03128879 ↗	Venetoclax and Ibrutinib in Treating Participants With High-Risk Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	Recruiting	National Cancer Institute (NCI)	Phase 2	2017-06-16	This phase II trial studies how well venetoclax and ibrutinib work in treating participants with high-risk chronic lymphocytic leukemia/small lymphocytic lymphoma. Drugs used in chemotherapy, such as venetoclax, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving venetoclax and ibrutinib may work better in treating participants with chronic lymphocytic leukemia/small lymphocytic lymphoma.
NCT03128879 ↗	Venetoclax and Ibrutinib in Treating Participants With High-Risk Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	Recruiting	M.D. Anderson Cancer Center	Phase 2	2017-06-16	This phase II trial studies how well venetoclax and ibrutinib work in treating participants with high-risk chronic lymphocytic leukemia/small lymphocytic lymphoma. Drugs used in chemotherapy, such as venetoclax, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving venetoclax and ibrutinib may work better in treating participants with chronic lymphocytic leukemia/small lymphocytic lymphoma.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for LOPURIN

Condition Name

Chart
Table

Condition Name for LOPURIN
Intervention	Trials
Chronic Lymphocytic Leukemia	2
PLCG2 Gene Mutation	1
Primary Lymphoid Haematopoietic Neoplasms	1
Small Lymphocytic Lymphoma	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for LOPURIN
Intervention	Trials
Leukemia, Lymphoid	3
Leukemia	3
Leukemia, Lymphocytic, Chronic, B-Cell	2
Leukemia, Myeloid, Acute	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for LOPURIN

Trials by Country

Map
Table

Trials by Country for LOPURIN
Location	Trials
United States	3
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for LOPURIN
Location	Trials
Texas	2
Minnesota	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for LOPURIN

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for LOPURIN
Clinical Trial Phase	Trials
Phase 2	2
N/A	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for LOPURIN
Clinical Trial Phase	Trials
Terminated	2
Recruiting	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for LOPURIN

Sponsor Name

Chart
Table

Sponsor Name for LOPURIN
Sponsor	Trials
M.D. Anderson Cancer Center	2
Celgene Corporation	1
Masonic Cancer Center, University of Minnesota	1
[disabled in preview]	2
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for LOPURIN
Sponsor	Trials
Other	3
Industry	2
NIH	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.